Armistice Capital’s Akari Therapeutics AKTX Stock Holding History

Armistice Capital’s Portfolio AKTX Stock Details AKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$200K	Sell	38,922 -29,177	-43%	-$273K	﹤0.01%	227
2025 Q4	$787K	Buy	+68,099	New	+$1.58M	0.01%	192
2023 Q1	–	Sell	-4,338	Closed	-$1.63M	–	228
2022 Q4	$1.63M	Sell	4,338 -1,025	-19%	-$424K	0.03%	120
2022 Q3	$2.7M	Buy	+5,363	New	+$4.42M	0.05%	117

Other funds holding AKTX

CAM

Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Truvestments Capital Sarasota, Florida $554M AUM 32.49% 1-Year Est. Return

Armistice Capital's AKTX Position: Q1 2026 in Review

Armistice Capital reduced its Akari Therapeutics (AKTX) stake by 43% in Q1 2026, selling an estimated $273K and leaving 38,922 shares worth $200K. The position accounts for ﹤0.01% of the portfolio, ranked #227.

Armistice Capital first reported a position in AKTX in Q3 2022 and has held it in 4 quarters since. The position peaked at $2.7M in Q3 2022. 6 funds tracked by Wall St. Rank hold AKTX as of Q1 2026.

Armistice Capital held 38,922 shares of Akari Therapeutics worth $200K as of Q1 2026.
Armistice Capital sold 29,177 Akari Therapeutics shares in Q1 2026, an estimated $273K.
Akari Therapeutics made up ﹤0.01% of Armistice Capital's portfolio in Q1 2026, its #227 holding.
Armistice Capital first reported a position in Akari Therapeutics in Q3 2022 and has held it in 4 quarters since.
Armistice Capital's Akari Therapeutics position peaked at $2.7M in Q3 2022.
6 funds tracked by Wall St. Rank held Akari Therapeutics as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.